Kyla D'angelo, DO
Cardiovascular Disease · Wethersfield, CTNPI 1669899829
Payments from drug & device makers
Across 144 payments — averaging $35.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$654
- Abbott$470
- Johnson & Johnson$458
- Boston Scientific$417
- Boehringer Ingelheim$320
- E.r. Squibb & Sons, L.L.C.$285
- plus $3K from 23 others
What the payments were for
- Consulting fees$250%
- Food & beverage$5,06299%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $654 |
| Abbott | 4 | $470 |
| Johnson & Johnson | 13 | $458 |
| Boston Scientific | 3 | $417 |
| Boehringer Ingelheim | 7 | $320 |
| E.r. Squibb & Sons, L.L.C. | 13 | $285 |
| Amgen | 9 | $273 |
| Pfizer | 11 | $265 |
| Alnylam Pharmaceuticals Inc. | 6 | $213 |
| Novartis | 8 | $197 |
| Scpharmaceuticals Inc. | 10 | $176 |
| Bridgebio Pharma, Inc. | 3 | $175 |
| AstraZeneca | 9 | $164 |
| Lexicon Pharmaceuticals, Inc. | 6 | $156 |
| Bracco Diagnostics Inc. | 1 | $144 |
| Bayer | 5 | $129 |
| Biotronik Inc. | 1 | $112 |
| Heartflow, Inc. | 2 | $101 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $74 |
| Merck | 3 | $71 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| Tactile Systems Technology Inc | 2 | $51 |
| Philips North America LLC | 1 | $29 |
| Baxter Healthcare | 1 | $25 |
| Angiodynamics, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$267
- XARELTO$250
- JARDIANCE$248
- JOT DX$244
- WATCHMAN FLX$149
- LUMASON$144
- Attruby$126
- Ozempic$125
- CARDIOMEMS$115
- BioMonitor$112
- Edora 8 DR-T$112
- Acticor 7 VR-T DX$112
- Rivacor 7 DR-T$112
- Confirm Rx$112
- Repatha$102
How this compares
$5,128 in reported general payments places this provider in the 70th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 599 | $843,220 |
| XareltoRivaroxaban | 185 | $258,219 |
| JardianceEmpagliflozin | 117 | $155,330 |
| Repatha SureclickEvolocumab | 62 | $79,067 |
| EntrestoSacubitril/Valsartan | 44 | $57,360 |
| FarxigaDapagliflozin Propanediol | 48 | $54,730 |
| BrilintaTicagrelor | 47 | $44,143 |
| Praluent PenAlirocumab | 47 | $36,611 |
| OzempicSemaglutide | 19 | $20,567 |
| VascepaIcosapent Ethyl | 24 | $15,131 |
| WegovySemaglutide | 11 | $14,869 |
| Metoprolol Succinate | 824 | $11,511 |
| Atorvastatin Calcium | 735 | $7,438 |
| Dofetilide | 21 | $7,176 |
| Rosuvastatin Calcium | 518 | $6,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $265 | $843,220599 claims |
| Johnson & JohnsonXarelto | $458 | $258,219185 claims |
| Boehringer IngelheimJardiance | $320 | $155,330117 claims |
| AstraZenecaFarxiga, Brilinta | $164 | $98,87395 claims |
| NovartisEntresto, Diovan | $197 | $61,34955 claims |
| Novo NordiskOzempic, Wegovy | $654 | $35,43530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Wethersfield
- Carol Gemayel BarraWethersfield$285K
- Komsu MamuyaWethersfield$25K
- Harlan KrumholzNew Haven$4M
- Jeffery TestaniNew Haven$3.4M
- Nihar DesaiNew Haven$3.2M
- Stuart ZarichBridgeport$1.3M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Brett NowlanBloomfield$798K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.